Lynn Kirkpatrick

Prolx Pharmaceuticals, Lp

$9,343,688

Attributed

$9,343,688

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.8M · FY2005–07

$2M$1.5M$1M$500K$0

'05

'06

'07

Funding mix

By agency

NIH$9,343,688 · 8

By mechanism

R44$8,105,134 · 3

R43$1,238,554 · 5

Top collaborators

No co-investigators on record.

Most similar at Prolx Pharmaceuticals, Lp

Same institution · by research overlap

Elizabeth R. Sharlow$1,800,275

Others in their field

Top investigators on “Drug Screening /Evaluation”

Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
John C S Breitner · Johns Hopkins University$33,065,187
Philip J Disaia · University Of California Irvine$21,551,991
George R Painter · Chimerix, Inc.$19,230,662
Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
Stephen J Durako · Westat, Inc.$15,048,684

Research focus

Drug Screening /EvaluationDrug Design /Synthesis /ProductionPharmacokineticsAntineoplasticsNeoplasm /Cancer PharmacologyScid MouseClinical Trial Phase IHuman SubjectThioredoxinDogsClinical ResearchInhibitor /AntagonistOncogenesSulfidesGene ExpressionBreast NeoplasmsKidney NeoplasmsDrug Adverse EffectDosageLaboratory RatCell LineNeoplastic CellLeukemiaDisulfide Bond